Iconovo focus on the part of the value chain where it can add significant value – the development of the inhalation product, while the customer brings its expertise in performing clinical trials, manufacturing, registration and sales.
Our customers license exclusive rights to a combination of substance(s) – inhaler – geography. A technology access fee is paid for the exclusive rights. Iconovo develops an inhalation product for the customer and the customer compensates Iconovo by paying development milestones. Once the product is launched, the customer pays Iconovo royalties for the use of licensed intellectual property.
Iconovo offers reliable, competitively priced dry powder inhaler solutions based on four proprietary differentiated technical platforms. Collaborating with Iconovo will give the customer a unique inhaler product at reduced project risk, lower development cost and shorter time to market.
Iconovo Product Pipeline
|Product candidate||Platform||Indication||Partner||Inhaler development||Formulation development||Clinical / Documentation||Registration|
|Budesonide, formoterol||ICOres™||Asthma, COPD||Amneal||Completed||On-going|
|Undisclosed substance(s)||ICOres™||Asthma, COPD||Intas||Completed||On-going|
|No substance||ICOcap™||Asthma, COPD||Stevanato||Completed||Not applicable||On-going|
|Indacaterol, glycopyrronium||ICOcap™||COPD||BNC Korea (regional)||Completed||On-going|
|Glycopyrronium||ICOcap™||COPD||BNC Korea (regional)||Completed||On-going|
|Oxytocin||ICOone™||postpartum hemorrhage||Monash University||Completed||Completed|
|Spike protein + adjuvant vaccine||ICOone™||Covid-19 infection||Immune System Regulation (ISR)||Completed||On-going|
|FluticasoneF, vilanterol||ICOpre™||Asthma, COPD||Available for licensing||On-going||On-going|